Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?
Saved in:
| Title: | Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most? |
|---|---|
| Authors: | O'Meara TA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Burstein HJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: Hal_burstein@dfci.harvard.edu. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Feb; Vol. 37 (2), pp. 133-135. Date of Electronic Publication: 2025 Oct 17. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
